SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (159)1/18/1999 12:32:00 PM
From: Abuckatatime  Read Replies (1) of 613
 
TD,

That article described the correction of hemophilia B in the models following intrahepatic (portal vein) infusion of the viral vector with no mention of the use of an ATRX drug delivery system. Were you presuming an ATRX connection? Perhaps I missed something. I see the authors with ties to Cell Genesys, Univ Of WA, Stanford U, and U of NC.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News